|
Gene: ADK |
Gene summary for ADK |
Gene summary. |
Gene information | Species | Human | Gene symbol | ADK | Gene ID | 132 |
Gene name | adenosine kinase | |
Gene Alias | AK | |
Cytomap | 10q22.2 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A140VJE0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
132 | ADK | CA_HPV_3 | Human | Cervix | CC | 5.40e-04 | 2.11e-01 | 0.0414 |
132 | ADK | CCI_1 | Human | Cervix | CC | 3.51e-19 | 1.46e+00 | 0.528 |
132 | ADK | CCI_2 | Human | Cervix | CC | 7.20e-19 | 2.21e+00 | 0.5249 |
132 | ADK | CCI_3 | Human | Cervix | CC | 4.17e-15 | 1.06e+00 | 0.516 |
132 | ADK | sample3 | Human | Cervix | CC | 1.35e-02 | 1.59e-01 | 0.1387 |
132 | ADK | T3 | Human | Cervix | CC | 1.17e-05 | 1.52e-01 | 0.1389 |
132 | ADK | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.66e-21 | -5.38e-01 | 0.0155 |
132 | ADK | HTA11_2487_2000001011 | Human | Colorectum | SER | 9.77e-07 | -5.74e-01 | -0.1808 |
132 | ADK | HTA11_2951_2000001011 | Human | Colorectum | AD | 1.98e-05 | -6.81e-01 | 0.0216 |
132 | ADK | HTA11_3361_2000001011 | Human | Colorectum | AD | 9.17e-18 | -7.12e-01 | -0.1207 |
132 | ADK | HTA11_696_2000001011 | Human | Colorectum | AD | 5.57e-03 | -2.96e-01 | -0.1464 |
132 | ADK | HTA11_866_2000001011 | Human | Colorectum | AD | 3.21e-03 | -3.15e-01 | -0.1001 |
132 | ADK | HTA11_5212_2000001011 | Human | Colorectum | AD | 2.35e-06 | -7.94e-01 | -0.2061 |
132 | ADK | HTA11_5216_2000001011 | Human | Colorectum | SER | 2.91e-03 | -5.44e-01 | -0.1462 |
132 | ADK | HTA11_9341_2000001011 | Human | Colorectum | SER | 7.87e-05 | -6.58e-01 | -0.00410000000000005 |
132 | ADK | HTA11_7862_2000001011 | Human | Colorectum | AD | 9.91e-06 | -6.11e-01 | -0.0179 |
132 | ADK | HTA11_866_3004761011 | Human | Colorectum | AD | 2.23e-09 | -5.14e-01 | 0.096 |
132 | ADK | HTA11_4255_2000001011 | Human | Colorectum | SER | 8.76e-03 | -4.38e-01 | 0.0446 |
132 | ADK | HTA11_9408_2000001011 | Human | Colorectum | AD | 9.03e-05 | -6.39e-01 | 0.0451 |
132 | ADK | HTA11_8622_2000001021 | Human | Colorectum | SER | 7.85e-05 | -5.09e-01 | 0.0528 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00091231 | Colorectum | MSI-H | nucleoside monophosphate metabolic process | 15/1319 | 76/18723 | 2.31e-04 | 6.03e-03 | 15 |
GO:0009127 | Colorectum | MSI-H | purine nucleoside monophosphate biosynthetic process | 7/1319 | 21/18723 | 4.09e-04 | 9.06e-03 | 7 |
GO:00091673 | Colorectum | MSI-H | purine ribonucleoside monophosphate metabolic process | 10/1319 | 41/18723 | 4.34e-04 | 9.42e-03 | 10 |
GO:00092002 | Colorectum | MSI-H | deoxyribonucleoside triphosphate metabolic process | 6/1319 | 17/18723 | 7.60e-04 | 1.42e-02 | 6 |
GO:0009265 | Colorectum | MSI-H | 2'-deoxyribonucleotide biosynthetic process | 5/1319 | 12/18723 | 8.97e-04 | 1.58e-02 | 5 |
GO:0046385 | Colorectum | MSI-H | deoxyribose phosphate biosynthetic process | 5/1319 | 12/18723 | 8.97e-04 | 1.58e-02 | 5 |
GO:00091173 | Colorectum | MSI-H | nucleotide metabolic process | 53/1319 | 489/18723 | 1.16e-03 | 1.92e-02 | 53 |
GO:0009394 | Colorectum | MSI-H | 2'-deoxyribonucleotide metabolic process | 9/1319 | 40/18723 | 1.55e-03 | 2.33e-02 | 9 |
GO:00067533 | Colorectum | MSI-H | nucleoside phosphate metabolic process | 53/1319 | 497/18723 | 1.66e-03 | 2.45e-02 | 53 |
GO:0009156 | Colorectum | MSI-H | ribonucleoside monophosphate biosynthetic process | 8/1319 | 33/18723 | 1.68e-03 | 2.47e-02 | 8 |
GO:00061633 | Colorectum | MSI-H | purine nucleotide metabolic process | 44/1319 | 396/18723 | 1.81e-03 | 2.61e-02 | 44 |
GO:00091413 | Colorectum | MSI-H | nucleoside triphosphate metabolic process | 17/1319 | 112/18723 | 2.13e-03 | 2.92e-02 | 17 |
GO:00091611 | Colorectum | MSI-H | ribonucleoside monophosphate metabolic process | 11/1319 | 58/18723 | 2.15e-03 | 2.92e-02 | 11 |
GO:0019692 | Colorectum | MSI-H | deoxyribose phosphate metabolic process | 9/1319 | 42/18723 | 2.22e-03 | 3.00e-02 | 9 |
GO:00725213 | Colorectum | MSI-H | purine-containing compound metabolic process | 45/1319 | 416/18723 | 2.73e-03 | 3.53e-02 | 45 |
GO:0009263 | Colorectum | MSI-H | deoxyribonucleotide biosynthetic process | 5/1319 | 15/18723 | 2.85e-03 | 3.63e-02 | 5 |
GO:0009262 | Colorectum | MSI-H | deoxyribonucleotide metabolic process | 9/1319 | 44/18723 | 3.12e-03 | 3.89e-02 | 9 |
GO:00091443 | Colorectum | MSI-H | purine nucleoside triphosphate metabolic process | 14/1319 | 88/18723 | 3.27e-03 | 3.99e-02 | 14 |
GO:00091503 | Colorectum | MSI-H | purine ribonucleotide metabolic process | 40/1319 | 368/18723 | 4.19e-03 | 4.73e-02 | 40 |
GO:00091504 | Colorectum | FAP | purine ribonucleotide metabolic process | 96/2622 | 368/18723 | 4.91e-10 | 1.20e-07 | 96 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa012325 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
hsa0123212 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
hsa01232 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
hsa012321 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
hsa012322 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
hsa012323 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
hsa012324 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
hsa0123211 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
hsa0123221 | Oral cavity | LP | Nucleotide metabolism | 42/2418 | 85/8465 | 3.62e-05 | 2.36e-04 | 1.52e-04 | 42 |
hsa0123231 | Oral cavity | LP | Nucleotide metabolism | 42/2418 | 85/8465 | 3.62e-05 | 2.36e-04 | 1.52e-04 | 42 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ADK | SNV | Missense_Mutation | novel | c.947N>C | p.Gly316Ala | p.G316A | P55263 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-C5-A1BF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
ADK | SNV | Missense_Mutation | novel | c.226G>A | p.Glu76Lys | p.E76K | P55263 | protein_coding | deleterious(0.01) | possibly_damaging(0.672) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ADK | SNV | Missense_Mutation | rs562751709 | c.830N>A | p.Arg277Gln | p.R277Q | P55263 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-G4-6586-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ADK | SNV | Missense_Mutation | c.44N>C | p.Val15Ala | p.V15A | P55263 | protein_coding | tolerated_low_confidence(0.16) | benign(0) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ADK | deletion | Frame_Shift_Del | rs771117099 | c.559delN | p.Thr190GlnfsTer8 | p.T190Qfs*8 | P55263 | protein_coding | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | ||
ADK | SNV | Missense_Mutation | novel | c.887N>C | p.Val296Ala | p.V296A | P55263 | protein_coding | deleterious(0.05) | benign(0.06) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ADK | SNV | Missense_Mutation | novel | c.128N>C | p.Asp43Ala | p.D43A | P55263 | protein_coding | tolerated(0.28) | benign(0.014) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
ADK | SNV | Missense_Mutation | novel | c.489G>T | p.Lys163Asn | p.K163N | P55263 | protein_coding | tolerated(0.62) | possibly_damaging(0.506) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ADK | SNV | Missense_Mutation | novel | c.989A>G | p.Asp330Gly | p.D330G | P55263 | protein_coding | tolerated(1) | benign(0) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ADK | SNV | Missense_Mutation | c.896N>G | p.Phe299Cys | p.F299C | P55263 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
132 | ADK | DRUGGABLE GENOME, ENZYME, KINASE | DABIGATRAN | DABIGATRAN | 22494098 | |
132 | ADK | DRUGGABLE GENOME, ENZYME, KINASE | GP-3269 | |||
132 | ADK | DRUGGABLE GENOME, ENZYME, KINASE | LOMUSTINE | LOMUSTINE | 6317371 | |
132 | ADK | DRUGGABLE GENOME, ENZYME, KINASE | 2,3-DIDEOXYADENOSINE | 3262616 | ||
132 | ADK | DRUGGABLE GENOME, ENZYME, KINASE | DACARBAZINE | DACARBAZINE | 6317371 | |
132 | ADK | DRUGGABLE GENOME, ENZYME, KINASE | BLEOMYCIN | BLEOMYCIN | 6317371 | |
132 | ADK | DRUGGABLE GENOME, ENZYME, KINASE | 2&APOS;,3&APOS;-DIDEOXYINOSINE | 3262616 | ||
132 | ADK | DRUGGABLE GENOME, ENZYME, KINASE | BUSULFAN | BUSULFAN | 6317371 | |
132 | ADK | DRUGGABLE GENOME, ENZYME, KINASE | inhibitor | 178101822 | ||
132 | ADK | DRUGGABLE GENOME, ENZYME, KINASE | inhibitor | 178101823 |
Page: 1 2 |